Sze-chuan Suen

Dr. Sze-chuan Suen


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HYHsin-Yun Yang
Hsin-Yun Yang
MBMatthew R. Beymer
Matthew R. Beymer
SSSze-chuan Suen
Sze-chuan Suen
People living with HIV/AIDS (PLWHA) have a growing life expectancy in the US due to early provision of effective antiretroviral treatment. This has resulted in increasing exposure to age-related chronic illness that may be exacerbated by HIV/AIDS or antiretroviral treatment. Prior work has suggested that PLWHA may be subject to accelerated aging, with earlier onset and higher risk of acquiring many chronic illnesses. However, the magnitude of these effects, controlling for chronic co-morbidities, has not been fully quantified. We evaluate the magnitude of association of HIV infection on developing chronic conditions while controlling for demographics, behavioral risk factors, and chronic comorbidities. We compare chronic disease risks of diabetes, hypertension, stroke, cancers, lung diseases, cardiovascular diseases, and cognitive impairment between PLWHA and HIV- individuals in a large, de-identified private insurance claims dataset (~24,000 PLWHA) using logistic regressions. HIV status is statistically significantly associated with higher levels for all chronic illnesses examined, a result which is robust to multiple model specifications and duration of analysis (2, 5, and 10 years from enrollment). Our results suggest that PLWHA may be at elevated risk for a wide variety of chronic illnesses and may require additional care as the aging PLWHA population grows.

21 July 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJonathan Salcedo
Jonathan Salcedo
MRMonica Rosales
Monica Rosales
JKJeniffer S. Kim
Jeniffer S. Kim
DNDaisy Nuno
Daisy Nuno
SSSze-chuan Suen
Sze-chuan Suen
ACAlicia H. Chang
Alicia H. Chang
Background: Tuberculosis (TB) incidence in Los Angeles County, California, USA (5.7 per 100,000) is significantly higher than the U.S. national average (2.9 per 100,000). Directly observed therapy (DOT) is the preferred strategy for active TB treatment but requires substantial resources. We partnered with the Los Angeles County Department of Public Health (LACDPH) to evaluate the cost-effectiveness of AiCure, an artificial intelligence (AI) platform that allows for automated treatment monitoring. Methods: We used a Markov model to compare DOT versus AiCure for active TB treatment in LA County. Each cohort transitioned between health states at rates estimated using data from a pilot study for AiCure (N = 43) and comparable historical controls for DOT (N = 71). We estimated total costs (2017, USD) and quality-adjusted life years (QALYs) over a 16-month horizon to calculate the incremental cost-effectiveness ratio (ICER) and net monetary benefits (NMB) of AiCure. To assess robustness, we conducted deterministic (DSA) and probabilistic sensitivity analyses (PSA). Results: For the average patient, AiCure was dominant over DOT. DOT treatment cost $4,894 and generated 1.03 QALYs over 16-months. AiCure treatment cost $2,668 for 1.05 QALYs. At willingness-to-pay threshold of $150K/QALY, incremental NMB per-patient under AiCure was $4,973. In univariate DSA, NMB were most sensitive to monthly doses and vocational nurse wage; however, AiCure remained dominant. In PSA, AiCure was dominant in 93.5% of 10,000 simulations (cost-effective in 96.4%). Conclusions: AiCure for treatment of active TB is cost-effective for patients in LA County, California. Increased use of AI platforms in other jurisdictions could facilitate the CDC’s vision of TB elimination.

30 June 2023 in World Journal of Surgery
Verified
Journal Article
Open access
PDF file
MSMatt Strickland
Matt Strickland
ANAnthony Nguyen
Anthony Nguyen
SWShinyi Wu
Shinyi Wu
SSSze-chuan Suen
Sze-chuan Suen
YMYanda Mu
Yanda Mu
KMKazuhide Matsushima
Kazuhide Matsushima
Background: Accurately predicting which patients are most likely to benefit from massive transfusion protocol (MTP) activation may help patients while saving blood products and limiting cost. The purpose of this study is to explore the use of modern machine learning (ML) methods to develop and validate a model that can accurately predict the need for massive blood transfusion (MBT).Methods: The institutional trauma registry was used to identify all trauma team activation cases between June 2015 and August 2019. We used an ML framework to explore multiple ML methods including logistic regression with forward and backward selection, logistic regression with lasso and ridge regularization, support vector machines (SVM), decision tree, random forest, naive Bayes, XGBoost, AdaBoost, and neural networks. Each model was then assessed using sensitivity, specificity, positive predictive value, and negative predictive value. Model performance was compared to that of existing scores including the Assessment of Blood Consumption (ABC) and the Revised Assessment of Bleeding and Transfusion (RABT).Results: A total of 2438 patients were included in the study, with 4.9% receiving MBT. All models besides decision tree and SVM attained an area under the curve (AUC) of above 0.75 (range: 0.75–0.83). Most of the ML models have higher sensitivity (0.55–0.83) than the ABC and RABT score (0.36 and 0.55, respectively) while maintaining comparable specificity (0.75–0.81; ABC 0.80 and RABT 0.83).Conclusions: Our ML models performed better than existing scores. Implementing an ML model in mobile computing devices or electronic health record has the potential to improve the usability.

31 August 2017 in Health Care Management Science
Verified
Journal Article
Closed access
PDF file
SSSze-chuan Suen
Sze-chuan Suen
MBMargaret L. Brandeau
Margaret L. Brandeau
JGJeremy D. Goldhaber-Fiebert
Jeremy D. Goldhaber-Fiebert

1 May 2022 in Operations Research
Verified
Journal Article
Closed access
SSSze-chuan Suen
Sze-chuan Suen
DNDiana Negoescu
Diana Negoescu
JGJoel Goh
Joel Goh
Designing Incentives to Promote Treatment Adherence Premature cessation of antibiotic therapy is common and can severely compromise health outcomes, potentially leading to worsening health, disease transmission, and antibiotic resistance. In “Design of Incentive Programs for Optimal Medication Adherence in the Presence of Observable Consumption,” Sze-chuan Suen, Diana Negoescu, and Joel Goh investigate the problem of designing a schedule of incentive payments to induce socially optimal treatment adherence levels in settings in which treatment adherence can be observed but patient preferences for treatment adherence are heterogeneous and unobservable to a health provider. The novel elements of this problem stem from its institutional features: there is a single incentive schedule applied to all patients, incentive payments must be increasing in patients’ adherence, and patients cannot be a priori prohibited from any given levels of adherence. The authors develop models to design optimal incentives incorporating these features and conduct a numerical study of the tuberculosis epidemic in India.

14 July 2020 in Health Economics
Verified
Journal Article
Open access
PDF file
MKMegumi Kasajima
Megumi Kasajima
HHHIDEKI HASHIMOTO
HIDEKI HASHIMOTO
SSSze-chuan Suen
Sze-chuan Suen
BCBrian Chen
Brian Chen
HJHawre Jalal
Hawre Jalal
JBJay Bhattacharya
Jay Bhattacharya
Accurate future projections of population health are imperative to plan for the future healthcare needs of a rapidly aging population. Multistate‐transition microsimulation models, such as the U.S. Future Elderly Model, address this need but require high‐quality panel data for calibration. We develop an alternative method that relaxes this data requirement, using repeated cross‐sectional representative surveys to estimate multistate‐transition contingency tables applied to Japan's population. We calculate the birth cohort sex‐specific prevalence of comorbidities using five waves of the governmental health surveys. Combining estimated comorbidity prevalence with death record information, we determine the transition probabilities of health statuses. We then construct a virtual Japanese population aged 60 and older as of 2013 and perform a microsimulation to project disease distributions to 2046. Our estimates replicate governmental projections of population pyramids and match the actual prevalence trends of comorbidities and the disease incidence rates reported in epidemiological studies in the past decade. Our future projections of cardiovascular diseases indicate lower prevalence than expected from static models, reflecting recent declining trends in disease incidence and fatality.